We have observed an enrichment of the ARID2 mutations in HCV-associated HCC in the US and European patient populations (6/43 tumors, 14%), compared with HBV-associated HCC in the Chinese population (1/50 tumors, 2%, P = 0.046) [16]. The gene discussed is ARID2; the disease is hepatocellular carcinoma.